Alzheimer-kór: vizsgálatok itt: Németország

In Németország 28 Also abroad 815

28 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.

2/3. fázisTaking people
A Study of Treatments for the Prevention of Disease Progression in Individuals at Risk for or With Early Onset Alzheimer’s Disease Caused by a Genetic Mutation
Where
Munich, Tuebingen
Életkor
18 év and over
People
27 worldwide
Run by
Washington University School Of Medicine
See details and how to join2024-517187-36-01 · EU 2024-517187-36-01
2/3. fázisTaking people
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
Where
Berlin, Boeblingen, Chemnitz, Ebersberg, Emmendingen, Munich
Életkor
55 év to 90 év
People
300 worldwide
Run by
Exciva GmbH
See details and how to joinNCT07284472 · EU 2024-517388-22-00
2. fázisTaking people
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
Where
Bamberg, Berlin, Bremen, Cologne, Hanover
Életkor
55 év to 85 év
People
160 worldwide
Run by
Sanofi
See details and how to joinNCT07688213 · EU 2025-524581-14-00
2. fázisTaking people
Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease
Where
Aachen, Berlin, Freiburg im Breisgau, Jena, Muenster, Munich
Életkor
50 év to 90 év
People
450 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07781657 · EU 2026-526158-14-00
3. fázisTaking people
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Where
Düsseldorf, Halle, Westerstede
Életkor
55 év to 90 év
People
426 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07011745 · EU 2025-520612-34-00
3. fázisTaking people
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Where
Erbach, Frankfurt Am Main
Életkor
55 év to 90 év
People
406 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00
3. fázisTaking people
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Where
Aachen, Berlin, Mainz, Mannheim, Muenster, Munich
Életkor
60 év to 85 év
People
586 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06976216 · EU 2025-520746-30-00
3. fázisTaking people
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Where
Boeblingen, Erbach, Frankfurt Am Main, Homburg
Életkor
55 év to 90 év
People
1000 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00
3. fázisTaking people
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Where
Düsseldorf, Halle, Westerstede
Életkor
55 év to 90 év
People
650 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00
No phaseTaking people
German Registry of Alzheimer's Disease Treated With Transcranial Pulse Stimulation
Where
Bonn, Kempen, Neuss, Oldenburg, Potsdam, Ulm
Életkor
18 év to 85 év
People
100
Run by
Heinrich-Heine University, Duesseldorf
See details and how to joinNCT06313944
2. fázisTaking people
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Where
Bremen, Munich
Életkor
40 év to 55 év
People
58 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07636811 · EU 2025-523390-42-00
3. fázisTaking people
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Where
Bad Homburg, Chemnitz, Cologne, Goettingen, Munich, Ulm
Életkor
60 év to 85 év
People
586 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06976203 · EU 2025-520747-32-00
No phaseTaking people
Dominantly Inherited Alzheimer Network (DIAN)
Where
Munich, Tübingen
Életkor
18 év and over
People
700 worldwide
Run by
Washington University School of Medicine
See details and how to joinNCT00869817
No phaseTaking people
Autophagy-Enhancers to Reduce Sleep Disturbances
Where
Greifswald
Életkor
55 év to 75 év
People
76
Run by
University Medicine Greifswald
See details and how to joinNCT07383311
3. fázisTaking people
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Where
Bayreuth, Böblingen, Homburg
Életkor
55 év to 90 év
People
410 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05511363
2/3. fázisTaking people
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Where
Munich, Tübingen
Életkor
18 év and over
People
280 worldwide
Run by
Washington University School of Medicine
See details and how to joinNCT05552157
2/3. fázisTaking people
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Where
Munich, Tübingen
Életkor
18 év and over
People
280 worldwide
Run by
Washington University School of Medicine
See details and how to joinNCT06647498
No phaseTaking people
Digital Dementia Registry Bavaria (digiDEM Bayern): a Multicentre, Prospective, Longitudinal Register Study Including People With Mild Cognitive Impairment and Dementia as Well as Their Family Caregivers
Where
Aschaffenburg, Bad Aibling, Bad Neustadt an der Saale, Bayreuth, Coburg, Freyung, München, Neumarkt, Nuremberg, Regensburg, Rosenheim
People
5000
Run by
University of Erlangen-Nürnberg Medical School
See details and how to joinNCT07721701
4. fázisTaking people
Patient- and care-related benefits of amyloid PET imaging (ENABLE)
Where
Berlin, Bonn, Cologne, Dresden, Erlangen, Essen, Freiburg im Breisgau, Goettingen, Greifswald, Hamburg, Leipzig, Magdeburg, Mainz, Mannheim, Marburg, Munich, Rostock, Tuebingen, Ulm
Életkor
18 év and over
People
1126
Run by
Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.
See details and how to join2023-503705-10-00 · EU 2023-503705-10-00
No phaseNot yet taking people in Németország
A Study Testing Whether Low-Dose Radiation Could Help the Immune System and Possibly Improve Early-Onset Alzheimer's Disease.
Where
Düsseldorf
Életkor
50 év and over
People
50
Run by
Heinrich-Heine University, Duesseldorf
See details and how to joinNCT07564700
1/2. fázisTaking people
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease
Where
Altenburg, Bad Homburg, Bochum, Goettingen, Köln, Mannheim, Ratingen
Életkor
50 év to 85 év
People
90 worldwide
Run by
NSC-Therapeutics
See details and how to joinNCT06995573 · EU 2024-518563-35-00
No phaseTaking people
COGSCREEN II: Early Detection of Cognitive Impairment
Where
München
Életkor
60 év and over
People
400
Run by
Robert Perneczky
See details and how to joinNCT07466394
No phaseTaking people
German Dementia Registry
Where
Aachen, Berlin, Bremen, Cologne, Erlangen, Essen, Frankfurt (Oder), Göttingen, Greifswald, Hamburg, Heidelberg, Homburg, Jena, Kiel, Klingenmünster, Leipzig, Magdeburg, Mainz, Mannheim, Rüdersdorf, Tübingen, Ulm
Életkor
18 év and over
People
5000
Run by
RWTH Aachen University
See details and how to joinNCT07433010
No phaseTaking people
VR Pupillometry in Cognitive Impairment
Where
München
Életkor
18 év to 80 év
People
140
Run by
Max-Planck-Institute of Psychiatry
See details and how to joinNCT07402356
2. fázisNot yet taking people in Németország
A Phase 2 Trial Evaluating the Effects of Thiethylperazine as diagnostic tool and therapeutic agent in Patients Diagnosed with an Early Stage of Alzheimer's disease
Where
Essen, Göttingen, Hanover, Mannheim, Munich, Rostock, Ulm
Életkor
18 év and over
People
228
Run by
Immungenetics AG
See details and how to join2022-501137-23-00 · EU 2022-501137-23-00